Eplerenone Reduces Atrial Fibrillation Burden Without Preventing Atrial Electrical Remodeling.

Abstract

BACKGROUND The aldosterone inhibitor eplerenone (EPL) has been shown to reduce the incidence of atrial fibrillation (AF) in patients with systolic heart failure, but the mechanism is unknown. OBJECTIVES This study hypothesized that by reducing atrial dilation and fibrosis in the absence of heart failure, EPL also reduces AF burden and prevents AF… (More)
DOI: 10.1016/j.jacc.2017.10.014

6 Figures and Tables

Topics

  • Presentations referencing similar topics